RT Journal Article
SR Electronic
T1 Genomic surveillance of SARS-CoV-2 during the first year of the pandemic in the Bronx enabled clinical and epidemiological inference
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.08.21250641
DO 10.1101/2021.02.08.21250641
A1 Fels, J. Maximilian
A1 Khan, Saad
A1 Forster, Ryan
A1 Skalina, Karin A.
A1 Sirichand, Surksha
A1 Fox, Amy S.
A1 Bergman, Aviv
A1 Mitchell, William B.
A1 Wolgast, Lucia R.
A1 Szymczak, Wendy
A1 Bortz, Robert H.
A1 Dieterle, M. Eugenia
A1 Florez, Catalina
A1 Haslwanter, Denise
A1 Jangra, Rohit K.
A1 Laudermilch, Ethan
A1 Wirchnianski, Ariel S.
A1 Barnhill, Jason
A1 Goldman, David L.
A1 Khine, Hnin
A1 Goldstein, D. Yitzchak
A1 Daily, Johanna P.
A1 Chandran, Kartik
A1 Kelly, Libusha
YR 2022
UL http://medrxiv.org/content/early/2022/03/17/2021.02.08.21250641.abstract
AB The Bronx was an early epicenter of the COVID-19 pandemic in the USA. We conducted temporal genomic surveillance of SARS-CoV-2 genomes across the Bronx from March-October 2020. Although the local structure of SARS-CoV-2 lineages mirrored those of New York City and New York State, temporal sampling revealed a dynamic and changing landscape of SARS-CoV-2 genomic diversity. Mapping the trajectories of variants, we found that while some became ‘endemic’ to the Bronx, other, novel variants rose in prevalence in the late summer/early fall. Geographically resolved genomes enabled us to distinguish between cases of reinfection and persistent infection in two pediatric patients. We propose that limited, targeted, temporal genomic surveillance has clinical and epidemiological utility in managing the ongoing COVID pandemic.One sentence summary Temporally and geographically resolved sequencing of SARS-CoV-2 genotypes enabled surveillance of novel genotypes, identification of endemic viral variants, and clinical inferences, in the first wave of the COVID-19 pandemic in the Bronx.Competing Interest StatementKC is a member of the scientific advisory boards of Integrum Scientific, LLC and the Pandemic Security Initiative of Celdara Medical, LLC..Funding StatementL.K. is supported in part by a Peer Reviewed Cancer Research Career Development Award from the United States Department of Defense (CA171019) (https://cdmrp.army.mil/funding/prcrp). S.K. was partially supported by the National Institutes of Health training grant 2T32GM007288-45 (Medical Scientist Training Program) at Albert Einstein College of Medicine (https://www.nigms.nih.gov/training/instpredoc/pages/predocoverview-mstp.aspx). Saad Khan (S.K) was supported an NIH T32 fellowship on Geographic Medicine and Emerging Infectious Diseases (2T32AI070117-13) (https://www.niaid.nih.gov/about/infectious-diseases-fellowship-application-information), and a grant from the Ullmann Family Foundation. Computational work was supported in part by an award from the Google Cloud Research Credits program (GCP19980904) (https://cloud.google.com/edu/researchers).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Institutional Review Board of Albert Einstein College of Medicine under IRB number 2016-6137.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences generated in this study have been made publicly available through the GISAID hCoV-19 sequence database. The source code used for sequencing, analysis, and figure generation, is hosted on Github at https://github.com/kellylab/genomic-surveillance-of-the-bronx. https://github.com/kellylab/genomic-surveillance-of-the-bronx